What is CORT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 12.73B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CORT?

P/E (TTM) is 233.19 and 52-week range is $28.66 to $126.38 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CORT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CORT?

The company profile lists revenue (TTM) near $759M, net income (TTM) near $50M, EPS (TTM) near $0.43 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Corcept Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 108.1M shares outstanding, ISIN US2183521028 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Corcept Therapeutics Inc

$CORT

Health Care · Pharmaceuticals

IR Run Scenarios

$117.80

-2.80%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 730 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Employees

730

Website

www.corcept.com/

IPO

2004-04-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)